Inotuzumab ozogamicin for R/R Ph- B-ALL 2L+ (bridge to alloHCT)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-INOTUZUMAB-OZOGAMICIN |
|---|
| ID | REG-INOTUZUMAB-B-ALL |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-INOVATE-KANTARJIAN-2016 SRC-NCCN-BCELL-2025 |
Notes
Anti-CD22 ADC for R/R Ph- B-ALL. INO-VATE: CR/CRi 80.7% vs 29.4%; MRD-neg 78.4% vs 28.1%. Bridge-to-HCT intent dominant. VOD/SOS boxed warning — limit pre-HCT exposure + avoid dual alkylator conditioning. STUB — pending Co-Lead sign-off.
Used By
Indication
IND-B-ALL-2L-INOTUZUMAB- IND-B-ALL-2L-INOTUZUMAB